| - Industry | - Sector | Mr. Niravkumar Kirtikumar Mehta CEO | MSE Exchange | - ISIN |
| India Country | 4,508 Employees | - Last Dividend | - Last Split | - IPO Date |
Corona Remedies Limited is an established Indian pharmaceutical formulation company dedicated to the development, manufacturing, and marketing of branded generic medicines. With a robust focus on multiple therapeutic areas, the company has made significant inroads into women’s healthcare, cardiology, pain management, urology, and various other chronic therapies. It boasts a diversified portfolio comprising dozens of brands, predominantly positioned in the mid-market segment. This strategic positioning allows Corona Remedies Limited to effectively target extensive prescription demand while maintaining healthy operating margins.
The company’s commercial operations span across India, bolstered by an extensive network of medical representatives and a wide distribution framework designed to reach doctors, hospitals, and pharmacies, especially in non-metro and underpenetrated markets. Financially, Corona Remedies Limited has shown a consistent upward trajectory in terms of revenue and profit growth, complemented by strong return ratios such as return on capital employed and return on equity. This performance illustrates the efficient utilization of capital within the business. Additionally, within the evolving healthcare ecosystem, the company plays a vital role in increasing the accessibility of essential therapies for chronic and lifestyle diseases in India's rapidly expanding domestic pharmaceutical market.